Fundraising Fox

Tenax Therapeutics

NASDAQ: TENX

Chapel Hill, US · Delaware corporation · 1 known investors

tenaxthera.com ↗

Tenax Therapeutics is a clinical-stage pharmaceutical company developing drug therapies for cardiovascular and pulmonary vascular diseases, including heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension. Its work focuses on cardiometabolic and cardiogenetic conditions.

BiotechDigital HealthHealthtechin /tenax-therapeutics

Founders & leadership

SR
Stuart RichChief Medical Officer
LR
Lawrence R. HoffmanInterim Chief Financial Officer
CT
Christopher T. GiordanoPresident and Chief Executive Officer
MB
Michael B. JebsenExecutive Officer
RR
Ronald R. BlanckDirector
GP
Gregory PepinDirector
JM
James MitchumDirector
CA
Chris A. RallisDirector
AD
Anthony DiTonnoDirector, Executive Officer
CG
Chris GiordanoPresident and Chief Executive Officer
DR
Doug RandallChief Business Officer
TS
Tom StaabChief Financial Officer

Investors · 1

Vivo CapitalPalo Alto · $10M – $50M

Reported raises · per SEC filings

Form D private placements
▶$99.7MraisedAug 2024 · 24 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael DavidsonDirector
  • Stuart RichExecutive Officer, Director
  • Lawrence R. HoffmanExecutive Officer
  • Christopher T. GiordanoExecutive Officer, Director
  • Declan DooganDirector
  • June AlmenoffDirector
  • Robyn M. HunterDirector
  • Gerald T. ProehlDirector
Offering amount
$175M
Amount sold
$99.7M
Sales commissions
$6.8M
Placement agents
Leerink Partners LLC, Guggenheim Securities, LLC, Roth Capital Partners, LLC, William Blair & Company, L.L.C.
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedJun 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith MaherDirector
  • Robyn HunterDirector
  • Michael DavidsonDirector
  • Christopher T. GiordanoExecutive Officer, Director
  • Steven BoydDirector
  • Declan DooganDirector
  • Eliot LurierExecutive Officer
  • Gerald ProehlDirector
  • June AlmenoffDirector
  • Stuart RichExecutive Officer, Director
Offering amount
$8M
Amount sold
$8M
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedJul 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael JebsenExecutive Officer
Offering amount
$10M
Amount sold
$10M
Sales commissions
$750K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.2MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael B. JebsenExecutive Officer
  • James MitchumDirector
  • Chris A. RallisDirector
  • Ronald R. BlanckDirector
  • Gerald ProehlDirector
  • Gregory PepinDirector
  • Anthony DiTonnoDirector, Executive Officer
Offering amount
$5.2M
Amount sold
$5.2M
Sales commissions
$1.4M
Placement agents
H.C. Wainwright & Co., LLC, Ladenburg Thalmann & Co. Inc.
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$317.2KraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael B. JebsenExecutive Officer
  • Ronald R. BlanckDirector
  • Gregory PepinDirector
  • James MitchumDirector
  • Chris A. RallisDirector
  • Gerald ProehlDirector
  • Anthony DiTonnoDirector, Executive Officer
Offering amount
$317.2K
Amount sold
$317.2K
Sales commissions
$206K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Mar 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.